# Precemtabart tocentecan

Source: https://onco.cc/drugs/precemtabart-tocentecan/  
OnCo record `precemtabart-tocentecan` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Precemtabart tocentecan is an experimental antibody-drug conjugate from EMD Serono Research & Development Institute in phase 3 trials for colorectal cancer, aimed at CEACAM5.

## Summary

Precemtabart tocentecan is an antibody-drug conjugate developed by EMD Serono Research & Development Institute. Its target is CEACAM5 (the sponsor names CEACAM5). The sponsor states: An antibody-drug conjugate against CEACAM5 carrying an exatecan (topoisomerase inhibitor) payload, given intravenously once every three weeks. ClinicalTrials.gov describes the intervention as: Precem-TcT, administered, once every 3 weeks intravenously, on Day 1 of each 21-day cycle. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT07549412 (A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)), in colorectal cancer. The largest, NCT07549412, plans to enrol 1020 participants with primary completion expected 2029-10-16. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Also known as: Precem-TcT
- Tags: pipeline; ctgov-ingest
- Modality: ADC
- Mechanism: An antibody-drug conjugate against CEACAM5 carrying an exatecan (topoisomerase inhibitor) payload, given intravenously once every three weeks.

## Sources

- ClinicalTrials.gov: trials of Precemtabart tocentecan: https://clinicaltrials.gov/search?intr=Precemtabart%20tocentecan

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- targets: [CEACAM5](https://onco.cc/targets/ceacam5/)
- companies: [Merck KGaA (EMD Serono)](https://onco.cc/companies/merck-kgaa/)
- trials: [A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)](https://onco.cc/trials/proceade-crc-03/), [Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)](https://onco.cc/trials/nct06710132/)

---
JSON: https://onco.cc/api/v1/entities/precemtabart-tocentecan.json